Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 219

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections.
- A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 6
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 11
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics under Development by Companies 13
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Products under Development by Companies 25
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Products under Investigation by Universities/Institutes 30
Companies Involved in Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Development 31
AlphaRx, Inc. 31
AstraZeneca PLC 32
Genentech, Inc. 33
Takeda Pharmaceutical Company Limited 34
Ceragenix Pharmaceuticals, Inc. 35
Piramal Healthcare Limited 36
Rib-X Pharmaceuticals, Inc. 37
Achillion Pharmaceuticals, Inc. 38
BioMarin Pharmaceutical Inc. 39
Forest Laboratories, Inc. 40
Wockhardt Limited 41
Paratek Pharmaceuticals, Inc. 42
Helix BioMedix, Inc. 43
Immtech Pharmaceuticals, Inc. 44
Lorus Therapeutics Inc 45
Basilea Pharmaceutica Ltd. 46
Biota Holdings Limited 47
Oragenics, Inc. 48
Theravance, Inc. 49
CrystalGenomics, Inc. 50
Phynova Group Ltd 51
Syntopix Group Plc 52
e-Therapeutics plc 53
Achaogen Inc. 54
Immupharma Plc 55
MerLion Pharmaceuticals Pte Ltd 56
Evolva SA 57
Novabiotics Ltd 58
MicuRx Pharmaceuticals, Inc. 59
Mondobiotech Holding AG 60
Destiny Pharma Ltd. 61
NovaDigm Therapeutics, Inc. 62
Kenta Biotech Ltd. 63
aRigen Pharmaceuticals, Inc. 64
Nabriva Therapeutics AG 65
Concert Pharmaceuticals, Inc. 66
Enanta Pharmaceuticals, Inc. 67
Canopus BioPharma Incorporated 68
Cempra Pharmaceuticals, Inc. 69
KYORIN Pharmaceutical Co., Ltd. 70
Trius Therapeutics, Inc. 71
Lytix Biopharma AS 72
Medisyn Technologies, Inc. 73
PALUMED S.A. 74
Phico Therapeutics Ltd. 75
Durata Therapeutics Inc. 76
Cantab Biopharmaceuticals Limited 77
PharmaIN Corporation 78
Excelimmune, Inc. 79
UNeMed 80
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Therapeutics Assessment 81
Assessment by Monotherapy Products 81
Assessment by Combination Products 82
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 88
dalbavancin - Drug Profile 88
AR-2474 - Drug Profile 90
plazomicin - Drug Profile 91
HB-1345 - Drug Profile 93
LOR-220 - Drug Profile 94
vancomycin formulation - Drug Profile 95
ceftaroline fosamil - Drug Profile 96
omadacycline - Drug Profile 98
PYN-6 - Drug Profile 100
LT-29 - Drug Profile 102
lotilibcin - Drug Profile 103
lotilibcin - Drug Profile 104
MX-2401 - Drug Profile 105
TD-1792 - Drug Profile 106
Antibiotic Program - Drug Profile 108
MU-1140 - Drug Profile 109
BC-7013 - Drug Profile 110
delafloxacin - Drug Profile 111
RX-04 - Drug Profile 114
KBSA-301 - Drug Profile 115
oxazolidinone - Drug Profile 116
XF-73 - Drug Profile 117
XF-73 - Drug Profile 118
Lipopeptide Programme - Drug Profile 119
CG-400549 - Drug Profile 120
WCK- 771 - Drug Profile 121
oritavancin disphosphate - Drug Profile 122
fusidic acid - Drug Profile 124
PM-181104 - Drug Profile 126
vancomycin - Drug Profile 127
PA-1245 - Drug Profile 128
ETX-1153b - Drug Profile 129
CDI Program - Drug Profile 130
NVB-333 - Drug Profile 131
torezolid - Drug Profile 132
Lipopeptide Program - Drug Profile 133
EDP-322 - Drug Profile 134
MRX-I - Drug Profile 135
Lytixar - Drug Profile 136
Cotrimoxazole - Drug Profile 138
SYN-0854 - Drug Profile 139
SYN-0096 - Drug Profile 140
ABI-0043 - Drug Profile 141
ceftobiprole medocaril - Drug Profile 142
IPP-203101 - Drug Profile 144
ceftaroline fosamil + avibactam sodium - Drug Profile 145
Co-trimaxazole - Drug Profile 147
Trimethoprim + Sulfamethoxazole + Cephalexin - Drug Profile 148
Trimethoprim + Sulfamethoxazole + Clindamycin - Drug Profile 149
CSA-13 - Drug Profile 151
Bactroban + Hibiclens - Drug Profile 153
levonadifloxacin - Drug Profile 154
WCK- 4086 - Drug Profile 155
MRX-II - Drug Profile 156
Systemic Antibiotic - Drug Profile 157
Topical Antibiotic Drug Program - Drug Profile 158
ACH-2881 - Drug Profile 159
secretin - Drug Profile 160
AMR-BAC-1 - Drug Profile 161
Drug For MRSA - Drug Profile 162
NDV-3 Vaccine - Drug Profile 163
SLP-0905 - Drug Profile 164
SLP-0906 - Drug Profile 166
SLP-1003 - Drug Profile 168
SLP-0904 - Drug Profile 170
SLP-1004 - Drug Profile 171
Anti-Bacterial Program - Drug Profile 173
PGC Anti-MRSA - Drug Profile 174
EP-67 - Drug Profile 175
SASPject PT1.2 - Drug Profile 176
Anti-MRSA Program - Drug Profile 178
Staphguard - Drug Profile 179
Bactericidal Venom-Based Polypeptides - Drug Profile 180
CF-301 - Drug Profile 181
Second Generation Oxas - Drug Profile 182
EV-035 - Drug Profile 183
KRP-AM1977X - Drug Profile 184
KRP-AM1977Y - Drug Profile 185
IMV-0123 - Drug Profile 186
Snare Antibacterial For MRSA - Drug Profile 187
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Drug Profile Updates 188
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Discontinued Products 204
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Dormant Products 205
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Product Development Milestones 206
Featured News & Press Releases 206
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 213
Disclaimer 213

List of Tables
Number of Products Under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H2 2012 17
Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Development by Companies, H2 2012 (Contd..2) 22
Number of Products under Development by Companies, H2 2012 (Contd..3) 23
Number of Products under Development by Companies, H2 2012 (Contd..4) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 26
Comparative Analysis by Late Stage Development, H2 2012 27
Comparative Analysis by Mid Clinical Stage Development, H2 2012 28
Comparative Analysis by Early Clinical Stage Development, H2 2012 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 30
Products under Development by Companies, H2 2012 31
Products under Development by Companies, H2 2012 (Contd..1) 32
Products under Development by Companies, H2 2012 (Contd..2) 33
Products under Development by Companies, H2 2012 (Contd..3) 34
Products under Development by Companies, H2 2012 (Contd..4) 35
Products under Investigation by Universities/Institutes, H2 2012 36
AlphaRx, Inc., H2 2012 37
AstraZeneca PLC, H2 2012 38
Genentech, Inc., H2 2012 39
Takeda Pharmaceutical Company Limited, H2 2012 40
Ceragenix Pharmaceuticals, Inc., H2 2012 41
Piramal Healthcare Limited, H2 2012 42
Rib-X Pharmaceuticals, Inc., H2 2012 43
Achillion Pharmaceuticals, Inc., H2 2012 44
BioMarin Pharmaceutical Inc., H2 2012 45
Forest Laboratories, Inc., H2 2012 46
Wockhardt Limited, H2 2012 47
Paratek Pharmaceuticals, Inc., H2 2012 48
Helix BioMedix, Inc., H2 2012 49
Immtech Pharmaceuticals, Inc., H2 2012 50
Lorus Therapeutics Inc, H2 2012 51
Basilea Pharmaceutica Ltd., H2 2012 52
Biota Holdings Limited, H2 2012 53
Oragenics, Inc., H2 2012 54
Theravance, Inc., H2 2012 55
CrystalGenomics, Inc., H2 2012 56
Phynova Group Ltd, H2 2012 57
Syntopix Group Plc, H2 2012 58
e-Therapeutics plc, H2 2012 59
Achaogen Inc., H2 2012 60
Immupharma Plc, H2 2012 61
MerLion Pharmaceuticals Pte Ltd, H2 2012 62
Evolva SA, H2 2012 63
Novabiotics Ltd, H2 2012 64
MicuRx Pharmaceuticals, Inc., H2 2012 65
Mondobiotech Holding AG, H2 2012 66
Destiny Pharma Ltd., H2 2012 67
NovaDigm Therapeutics, Inc., H2 2012 68
Kenta Biotech Ltd., H2 2012 69
aRigen Pharmaceuticals, Inc., H2 2012 70
Nabriva Therapeutics AG, H2 2012 71
Concert Pharmaceuticals, Inc., H2 2012 72
Enanta Pharmaceuticals, Inc., H2 2012 73
Canopus BioPharma Incorporated, H2 2012 74
Cempra Pharmaceuticals, Inc., H2 2012 75
KYORIN Pharmaceutical Co., Ltd., H2 2012 76
Trius Therapeutics, Inc., H2 2012 77
Lytix Biopharma AS, H2 2012 78
Medisyn Technologies, Inc., H2 2012 79
PALUMED S.A., H2 2012 80
Phico Therapeutics Ltd., H2 2012 81
Durata Therapeutics Inc., H2 2012 82
Cantab Biopharmaceuticals Limited, H2 2012 83
PharmaIN Corporation, H2 2012 84
Excelimmune, Inc., H2 2012 85
UNeMed, H2 2012 86
Assessment by Monotherapy Products, H2 2012 87
Assessment by Combination Products, H2 2012 88
Assessment by Stage and Route of Administration, H2 2012 90
Assessment by Stage and Molecule Type, H2 2012 93
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Drug Profile Updates 194
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Discontinued Products 210
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Dormant Products 211

List of Figures
Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H2 2012 17
Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 25
Late Stage Products, H2 2012 27
Mid Clinical Stage Products, H2 2012 28
Early Clinical Stage Products, H2 2012 29
Discovery and Pre-Clinical Stage Products, H2 2012 30
Assessment by Monotherapy Products, H2 2012 87
Assessment by Combination Products, H2 2012 88
Assessment by Route of Administration, H2 2012 89
Assessment by Stage and Route of Administration, H2 2012 90
Assessment by Molecule Type, H2 2012 91
Assessment by Stage and Molecule Type, H2 2012 92

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Fungal Infections - Pipeline Review, H2 2012
• Methicillin-Resistant Staphylococcus Aureus (Event Driven)
• Influenza A Infections - Pipeline Review, H2 2012
• Mycobacterium Infections - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Mycoses - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Respiratory Tract Infections - Pipeline Review, H2 2012